



PATENT  
Customer No. 22,852  
Attorney Docket No. 04012.0384-00000

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Reissue Application of:	)	
	)	
Lucas-Laskey et al.	)	Group Art Unit: 1614
	)	
Application No.: 10/721,022	)	Examiner: P. Spivack
	)	
Original Patent No. 5,902, 821	)	
	)	Confirmation No.: 3995
Original Issue Date: May 11, 1999	)	
	)	
Reissue Filed: November 25, 2003	)	
	)	
For: USE OF CARBAZOLE	)	
COMPOUNDS FOR THE	)	
TREATMENT OF CONGESTIVE	)	
HEART FAILURE	)	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the information on the attached listing. This Supplemental Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Supplemental Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

03/13/2006 52EWD1E1 00000056 10/721022

03 FC:1006

180.00 OP

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form. Copies of the listed non-patent literature documents are attached.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to Deposit Account No. 06-0916.


Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: March 10, 2006

By:   
Mark J. Feldstein  
Reg. No. 46,693

IDS Form PTO/SB/08: Substitute for form 1449A/PTO  <div style="text-align: center;"><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></div> <div style="text-align: center; font-size: small;">(Use as many sheets as necessary)</div>				<div style="text-align: right; font-weight: bold;">Complete if Known</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/721,022</td> </tr> <tr> <td>Filing Date</td> <td>November 25, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Lucas-Laskey et al</td> </tr> <tr> <td>Art Unit</td> <td>1614</td> </tr> <tr> <td>Examiner Name</td> <td>P. Spivack</td> </tr> <tr> <td>Attorney Docket Number</td> <td>04012.0384-00000</td> </tr> </table>		Application Number	10/721,022	Filing Date	November 25, 2003	First Named Inventor	Lucas-Laskey et al	Art Unit	1614	Examiner Name	P. Spivack	Attorney Docket Number	04012.0384-00000
Application Number	10/721,022																
Filing Date	November 25, 2003																
First Named Inventor	Lucas-Laskey et al																
Art Unit	1614																
Examiner Name	P. Spivack																
Attorney Docket Number	04012.0384-00000																
Sheet	1	of	1														



U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
	1	<i>Bristol Meyers Squibb v. Ben Venue Labs.</i> , 246 F.3d 1368 (Fed. Cir. 2001).	
	2	<i>Rapoport v. Dement</i> , 254 F.3d 1053 (Fed. Cir. 2001).	
	3	<i>Jansen v. Rexall Sundown, Inc.</i> , 342 F.3d 1329, 1333-34 (Fed. Cir. 2003).	
	4	<i>Glaxo Group Ltd. v. Teva Pharma, Inc.</i> , 2004 U.S. Dist. LEXIS 16750, at *56-57 (D. Del. 2004).	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.